Introduction
Long-range gene activation plays a prominent role in metazoan gene expression (reviewed in Dean [2006] ). Transcription determinants can be separated from their target promoters by thousands of base pairs. In some cases, these distal regulatory elements are involved in the activation of multiple promoters within a gene cluster, switching from one to another in a developmentally controlled or tissue-specific manner (Li et al., 2002; Ho et al., 2004) . Defining the mechanisms mediating these long-range interactions remains a major challenge in the field of eukaryotic gene expression.
Locus control regions (LCRs) encompass an intensively characterized group of long-range transcriptional control determinants. An LCR is defined as a set of elements sufficient to generate an autonomous chromatin environment (Grosveld et al., 1987; Festenstein et al., 1996) . Characteristically, LCR components colocalize with DNase I hypersensitive sites (HS) in the chromatin of expressing cells. The mechanisms of LCR action at different loci appear to be quite diverse (Dean, 2006) . Understanding how these determinants activate gene expression over extensive distances is clearly central to defining critical pathways of transcriptional regulation.
Mammalian nuclei contain thousands of transcripts that do not correspond to known structural genes or to RNAs with defined functions. The vast majority of these intergenic transcripts are likely to constitute background ''noise'' in the transcriptome. However, accumulating evidence indicates that in particular situations these transcripts have essential functions in gene expression (Plath et al., 2002) . In some cases the process of intergenic transcription, rather than its RNA product, may directly impact on chromatin structure (Schmitt et al., 2005) . The importance of noncoding transcription in gene regulation is supported by reports of transcription through regions encompassing a number of LCRs (Masternak et al., 2003; Ashe et al., 1997; Routledge and Proudfoot 2002) . Although transcription through regulatory domains may correlate with expression of linked genes (Gribnau et al., 2000) , it remains unclear whether this process represents an active role in gene regulation or, alternatively, reflects promiscuous transcription through already ''open'' chromatin regions.
The human growth hormone (hGH) cluster contains five highly conserved genes (Chen et al., 1989) ( Figure 1A , top). hGH-N is specifically expressed in pituitary somatotropes while expression of hCS-L, hCS-A, hGH-V, and hCS-B is restricted to placental syncytiotrophoblasts. This cluster is controlled by a remote LCR (hGH LCR) comprising five DNase I HS located 214.5 to 232 kb 5 0 to the hGH-N gene (Jones et al., 1995; Su et al., 2000) . Closely linked HSI and HSII are pituitary specific, HSIV is placental specific, and HSIII and HSV are present in both tissues. The hGH LCR and the hGH-N promoter are encompassed by a continuous 32 kb pituitary-specific domain of acetylated histones H3 and H4 with a central peak located at HSI (Elefant et al., 2000) . Site-specific inactivation of HSI results in loss of acetylation throughout this domain, loss of critical transfactor occupancy at the hGH-N promoter, and a 20-fold reduction in hGH-N expression (Ho et al., 2002) . Thus, HSI plays an essential role in the establishment of the acetylated domain and in activation of hGH-N transcription in the pituitary. Whether the longrange activating capacity of HSI is limited to its acetylating function or reflects a more complex mechanism is currently unclear.
Here we report that HSI has a second and apparently independent role in hGH-N activation. The data revealed that HSI plays an essential role in the establishment of a complex domain of intergenic transcription 5 0 to the hGH cluster. Insertion of an exogenous transcriptional terminator within this domain selectively blocked a subset of downstream LCR transcripts and repressed hGH-N transcription. These changes occurred in the absence of appreciable alterations in histone acetylation within the hGH locus. These data lead us to conclude that the remote transcriptional domain plays a direct role in LCR-mediated, long-range gene activation.
Results
The hGH LCR Is Transcribed in a Pituitary-Specific and HSI-Dependent Manner The hGH/P1 transgene contains the entire hGH LCR and first four genes of the hGH gene cluster (Figure 1) (Su et al., 2000) . In the hGH/P1 transgenic mouse pituitary, a 32 kb acetylated chromatin domain extends from a 5 0 boundary at HSV to a 3 0 terminus that encompasses the hGH-N promoter (Elefant et al., 2000) . This chromatin structure at the hGH transgene accurately replicates chromatin modifications detected in the human pituitary (Elefant et al., 2000) . Inactivation of HSI in the hGH/P1 transgene results in loss of LCR acetylation and repression of hGH-N transgene expression (Ho et al., 2002) . These data suggested a model in which HAT complexes are recruited to HSI and subsequently spread bidirectionally to establish the modified chromatin domain and activate hGH-N (Ho et al., 2002) . Studies documenting association of HAT complexes with Pol II (Wittschieben et al., 1999) suggest that polymerase may serve as a ''motor'' for spreading chromatin-modifying complexes. (Top) Map of the hGH locus and the hGH/P1 transgene. A 100 kb region of the human genome on chromosome 17q22 is shown. Each structural gene is shown as a rectangle with its corresponding transcriptional orientation indicated by an angled arrow. The five DNase I HS that constitute the hGH LCR are indicated (upward arrows with Roman numerals), as is the extent of the hGH/P1 transgene (bracketed line below the map). A slightly expanded view of the region encompassing the hGH-N gene is shown with the relative positions of the 12 RT-PCR amplimers (short bars) used to detect transcripts. Note that the HSI amplimer used in these studies detects sequences that are adjacent to, but not included within, the 99 bp HSI deletion site in the hGH/P1(DHSI) transgene. Also, the p9 amplimer corresponds to a common sequence present 5 0 to each of the four placentally expressed genes in the cluster. (Bottom) Transcripts are present throughout the hGH LCR and are both pituitary specific and HSI dependent. The histogram summarizes relative levels of transcripts (y axis) at 12 sites throughout the hGH locus and are plotted in alignment with the corresponding amplimer sets (top). The transcripts were detected by a semiquantitative PCR survey of cDNA libraries generated from randomly primed total cellular RNA samples. These values, represented in arbitrary units, were calculated as a ratio between the RT/PCR amplification at each site and the corresponding amplification from the plasmid control template (hGH/P1). The autoradiograph insets show representative studies corresponding to six of the sites. A line connects each representative autoradiograph to its relevant three bar set of histograms. The PCR products were quantified by phosphorimager analysis and normalized to signals of the PCR products from 0.007 ng of control hGH/P1 plasmid DNA (C) using the same set of PCR primers. The PCR products represent analyses of pituitary RNA (Pit) from hGH/P1 (P1, white bars) and hGH/P1(DHSI) (D, gray bars) lines, and hepatic RNA from an hGH/P1 mouse (Liv, black bars). Two hGH/P1 lines and two hGH/P1(DHSI) lines were studied in each of two independent assays. Each histogram bar represents the average 6SD from these four independent assays. The values for liver RNAs reflect an average value from independent analyses of liver RNA isolated from two mice from each of two hGH/P1 transgenic lines. RT-PCR analyses for b-actin mRNA (inset at the bottom of the figure) were carried out on each sample to control for adequacy of the respective RNA preparation.
Such a model would predict a tight linkage between histone acetylation and intergenic transcription through the hGH LCR.
To determine whether polymerase tracks through the hGH LCR, this region was probed for corresponding transcripts. RNA isolated from somatotrope-enriched pituitaries of hGH/P1 transgenic mice was randomly primed to generate a cDNA library. This library was surveyed with a series of site-specific PCR amplimers (Figure 1 and see Table S1 in the Supplemental Data available with this article online). Relative levels of transcripts, normalized to internal controls, were determined across the locus. Transcripts were detected at sites extending from 221 kb relative to the transcriptional start site of hGH-N through the CD79b region (Figure 1 histogram, white bars, from amplimers p5 through CD79b[Ex6]). Transcript levels within the LCR (amplimers p5, p4, HSI, and p3) ranged from 10% to 20% that of the hGH-N mRNA. Regions between HSV and p5 could not be accurately assessed due to the high levels of sequence conservation between the human and mouse SCN4a gene exons. There was minimal evidence of transcripts at the 5 0 boundary of the LCR (amplimer HSV) or 3.6 kb further 5 0 (amplimer p7). A high density of transcripts was detected immediately 3 0 to HSI in the region corresponding to CD79b. This transcription across the CD79b gene was comparable to that at hGH-N (compare CD79b[Ex6] with hGH-N[Ex5]) and was in agreement with our prior report of robust CD79b bystander transcription in the pituitary (Cajiao et al., 2004) . Transcript levels fall abruptly 3 0 of CD79b, consistent with the action of CD79b 3 0 processing signals. As expected, hGH-N was itself robustly transcribed and transcription returned to background levels within the region of the cluster containing the placentally expressed genes (p9 amplimer). Analysis of mice carrying hGH/P1 transgene with a 99 bp deletion that removes critical HSI determinants (hGH/P1[DHIS]); Ho et al., 2002 ) reveals a marked repression of transcription throughout the hGH LCR and adjacent CD79b (Figure 1 histogram, gray bars). The entire hGH locus was transcriptionally inactive in hepatic RNA of an hGH/P1 mouse (Figure 1, black bars) . In summary, these data revealed that the hGH LCR is transcribed, that this domain of transcription extends to include the contiguous CD79b gene, and that transcription of this entire region is pituitary specific and HSI dependent. Because of the shared HSI dependence of intergenic transcription within the LCR (5 0 to HSI) and through the contiguous CD79b (3 0 to HSI), we refer to these two regions collectively as the LCR domain of transcription.
Transcript orientations throughout the hGH/P1 transgene locus were assessed by strand-specific RT/PCR (Figure 2 ). The strand specificity of this assay was validated by the 15-fold predominance of sense transcripts at hGH-N. We found a similar predominance of senseoriented transcripts at CD79b. In contrast, transcription of the LCR 5 0 to CD79b was bidirectional with no more than a 2-fold excess of one orientation over another. In summary, these data revealed that the robust, HSI-dependent LCR domain of transcription is Figure 1 ). Each RT reaction was performed using a sense or antisense specific primer from the relevant amplimer set. (Bottom) Relative levels of antisense and sense transcripts within the hGH LCR. Strand-specific RT reactions were followed by PCR reactions corresponding to the amplimer sites indicated above. The results were quantified by Southern blot hybridization with unique sequence probes and calculated (as in Figure 1 ). Each bar represents the average 6SD value from four independent studies. A representative data set is displayed below the histogram. Amplification products are shown in the presence and absence of reverse transcriptase (RTase), and the polarity of the initial strand-specific RT primer, antisense (AS), or sense (S) is indicated. The control PCR used 0.007 ng hGH/P1 plasmid DNA as template (C), a value demonstrated by serial dilutions to be in the linear range of detection (data not shown).
complex-bidirectional 5 0 of CD79b, but transcribed in the ''sense'' orientation through CD79b.
The hGH LCR Is Transcribed by RNA Polymerase II Transcription through the hGH locus was further characterized by Pol II chromatin immunoprecipitation (ChIP) (Figure 3 ). The amplimers used in this study correspond to a set of unique sequences across the hGH locus (Figure 3A ; Table S2 ). The ratio of DNA in the bound versus input sample at each position was assessed across the locus by semiquantitative PCR (Ho et al., 2002) . The endogenous myoD gene, expressed specifically in skeletal muscle, served as the normalization control for the ChIP studies (Sawado et al., 2003) . The initial ChIP was carried out with an antibody to the N terminus of Pol II that recognizes all RNA Pol II isoforms ( Figure 3B ). Each study was performed twice on tissue samples isolated from each of two hGH/P1 lines (809F and 811D; Su et al., 2000) . The data revealed that levels of Pol II increased from very low abundance at the 5 0 end of the LCR to substantial levels more central to the LCR and at CD79b ( Figure 3B , white bars). Pol II occupancy dropped off 3 0 of CD79b and did not become significant again until the hGH-N promoter was encountered. The hGH-N promoter and coding region had high Pol II concentrations, and Pol II occupancy dropped to minimal levels within the placentally expressed genes of the cluster (at amplimer p9).
The relationship between Pol II activity and LCR function was assessed by ChIP analysis of two hGH/ P1(DHSI) lines (960G and 969E; Ho et al., 2002) . Analysis of pituitary chromatin from mice with the HSI deletion demonstrated levels of Pol II occupancy throughout the LCR domain of transcription that were substantially lower than those seen in the hGH/P1 transgene (Figure 3B , gray bars). Pol II occupancy in hepatic chromatin Table S2 ). The data in (B) and (C) are aligned below the corresponding amplimer sets. (B) ChIP analyses for total Pol II in transgenic pituitary and liver chromatin. The antibody used in this ChIP assay is specific to the N terminus of Pol II and recognizes all isoforms. Each bar represents the average 6SD of six independent assays of the indicated chromatin samples: hGH/P1 pituitary chromatin (white bars), hGH/P1(DHSI) pituitary chromatin (gray bars), or control hGH/P1 liver chromatin (black bars). The values represent a ratio of the DNA signal detected in the immunoprecipitated sample to that in the corresponding input sample. The ''Total Pol II Occupancy'' values on the y axis are in arbitrary units. (C) ChIP analysis of elongating pPol II in transgenic pituitary and liver chromatin. The antibody used for these ChIP studies recognizes the Ser5-phosphorylated residues in the C-terminal domain of Pol II (pPol II). The data, generated as in (B), represent the average 6SD from four independent assays of each indicated chromatin sample. Each set of histogram bars represents occupancy in the hGH/P1 pituitary, hGH/P1(DHSI) pituitary, and hGH/P1 liver, as in (B).
from the hGH/P1 transgenic lines was at background levels ( Figure 3B , black bars). Comparison of the hGH/ P1(DHSI) pituitary chromatin ChIP analyses with that of the hGH/P1 hepatic chromatin revealed that the CD79b and hGH-N loci retained low but significant levels of Pol II in pituitary chromatin. These residual levels of Pol II in the absence of HSI are consistent with the 5% residual level of pituitary hGH-N transcription from the hGH/P1(DHSI) transgene (Ho et al., 2002) . From these studies, we conclude that Pol II is recruited to the hGH LCR and that this recruitment is pituitary specific and HSI dependent.
A second series of Pol II ChIPs was carried out using an antibody specific for the elongating isoform of Pol II (Ser-5 phosphorylated C-terminal domain [CTD] ; pPol II) (Orphanides and Reinberg, 2002) (Figure 3C ). The distribution of elongating pPol II at the hGH locus in pituitary chromatin was similar to that of total Pol II (compare Figures 3B and 3C, white bars). Of note, the hGH-N promoter was selectively enriched for nonphosphorylated Pol II when compared to the structural gene. This is consistent with direct recruitment of unphosphorylated Pol II to the hGH-N promoter and its subsequent conversion to the CTD-phosphorylated pPol II form as it is released and initiates elongation (Dahmus, 1996) . Deletion of HSI resulted in a marked loss of pPol II throughout the locus ( Figure 3C , gray bars), and there was no appreciable pPol II occupancy at the hGH/P1 transgene locus in hepatic chromatin ( Figure 3C , black bars). The parallel between the distributions of elongating pPol II and the intergenic RNA transcripts, and their shared dependence on HSI activity, leads us to conclude that the LCR domain of transcription in the pituitary is generated by Pol II tracking through this region.
The hGH LCR Domain of Transcription Plays an Essential Role in Long-Range hGH-N Activation To test whether Pol II tracking plays a direct role in hGH LCR action, an exogenous Pol II termination element was inserted within the LCR domain of transcription ( Figure 4 top; TerF). The 2.2 kb ''Ter F'' fragment corresponds to a segment of the human b-globin gene extending from exon 2 through its 3 0 -flanking region Proudfoot, 1999, 2001 ) (see Figure S1 ). TerF targets efficient 3 0 processing of nascent Pol II transcripts and triggers subsequent dissociation of Pol II from the DNA template at the cotranscriptional cleavage site (CoTC) Teixeira et al., 2004) . TerF was inserted in the sense orientation relative to the hGH cluster at a site 1.5 kb 3 0 of HSI. The goal of this insertion was to selectively block HSI-dependent transcription through CD79b. Five mouse lines carrying the hGH/P1(TerF) transgene were generated, and the transgene copy number of each line was determined by Southern blot analysis (Su et al., 2000) (data not shown). Analysis of pituitary transcripts from mice representing each of the five lines revealed a mean 5-fold drop in the levels of transcripts from a site 5 0 of the CoTC to a site 3 0 of the CoTC region (see Figure S1 ). This drop was consistent with the CoTC termination function (Dye and Proudfoot, 2001) .
Having established that the TerF element was functioning in vivo to terminate transcription at a site 3
0 to HSI, we tested the model that Pol II tracking is directly related to establishment of histone H3/H4 acetylation within the hGH locus. Pituitary chromatin samples isolated from mice carrying hGH/P1(TerF) (lines 1301C and 1301G) were analyzed by ChIP assays using antibodies specific for acetylated histones H3 and H4 (Figure 4) . Comparative ChIP assays were performed in parallel on pituitary chromatin from hGH/P1 and hGH/ P1(DHSI) mouse lines. Analysis of the hGH/P1 transgenic pituitary chromatin confirmed the previously reported hyperacetylation of the hGH LCR and the hGH-N promoter (Elefant et al., 2000; Ho et al., 2002) . The dramatic loss of acetylation across this region in hGH/P1(DHSI) transgenic pituitary chromatin confirmed the dependence of these modifications on HSI activity (Figure 4) (Ho et al., 2002) . Remarkably, the analysis of the hGH/P1(TerF) lines revealed that insertion of TerF within the LCR domain of transcription had no appreciable impact on histone H3/H4 acetylation either 5 0 or 3 0 of the insertion site (Figure 4 ). Of particular note, full levels of core histone H3/H4 acetylation were maintained at the hGH-N promoter. These data suggest that the establishment and/or maintenance of the extensive and continuous domain of histone acetylation between the hGH LCR and the hGH-N promoter is not linked to Pol II tracking through this region.
In light of the observation that TerF insertion within the domain of LCR transcription had no apparent effect on histone H3/H4 acetylation (Figure 4) , we next directly assessed the impact of the TerF insertion on transcription through the locus. Transcript levels were assayed at two sites 5 0 of the TerF insertion and at a site 3 0 of its insertion ( Figure 5A ). These values were normalized to actin mRNA levels and compared to levels at the corresponding sites in two representative hGH/P1 lines. Although the TerF insertion had no significant impact on transcripts 5 0 to its insertion site, it resulted in a 5-fold mean decrease in levels of transcripts 3 0 to its insertion. Thus, the TerF insertion resulted in a unilateral, downstream repression of transcripts within the LCR domain of transcription. This selective impact within the transcription domain is consistent with the orientation and position of the TerF insertion.
To address whether LCR transcription plays a direct role in hGH-N gene expression, the impact of the TerF insertion on hGH-N transcription was determined in each of the five hGH/P1(TerF) lines and compared to two hGH/P1 lines ( Figure 5B) . hGH-N mRNA in each transgenic pituitary was quantified relative to endogenous mGH mRNA and normalized to transgene copy number. The normalized transgene expression levels among the five hGH/P1(TerF) lines were highly consistent with less than a 2-fold variation between the highest and lowest values. The mean hGH-N expression in these lines was 6-fold below that in two hGH/P1 lines. These data lead us to conclude that Pol II tracking within the LCR domain of transcription is integral to long-range control of the hGH-N promoter.
Discussion
The hGH LCR Establishes a Domain of Pol II Transcription 5 0 to the hGH-N Gene The hGH gene cluster presents a challenging and potentially informative model of long-range control.
Its activation in the pituitary and placenta is dependent on overlapping sets of LCR determinants. These LCR determinants mediate distinct patterns of chromatin modifications and activate different subsets of genes from the hGH gene cluster in these two tissues (Ho et al., 2002; Kimura et al., 2004) . Additional complexity at this locus is introduced by the B-lymphocyte-specific gene, CD79b, which is interposed between the hGH LCR and the hGH cluster (Bennani-Baïti et al., 1998), and by the location of HSIII-HSV within the adjacent striated muscle sodium channel gene, SCN4A ( Figure 1A) .
Defining how the hGH LCR functions in this environment tightly packed with tissue-specific genes and how each of these genes selectively expresses its protein product only in its corresponding tissue should yield significant insights into these complex processes.
The current study focuses on LCR-mediated activation of hGH-N in the pituitary. The hGH LCR and the hGH-N promoter are located in a continuous, HSI-dependent domain of acetylated chromatin in primary human pituitary tissue and in the pituitaries of mice carrying the hGH transgene locus (Elefant et al., 2000; 0 of the insertion. Sequential dilutions of the input chromatin sample are shown along with a single linear-range dilution of the bound fraction. The ratio of bound/input was normalized to the corresponding ratio of bound/input chromatin at the MyoD locus. The value on the y axis reflects the final normalized ratio. The values for hGH/P1(TerF) (white bars) represent the average for two lines analyzed (1301C and 1301G). Ho et al., 2002) . These data support a model in which histone acetyltransferase (HAT) complexes are recruited to HSI and subsequently spread bidirectionally, 5 0 to a boundary at HSV and 3 0 to encompass and activate the hGH-N promoter. It has been further proposed that Pol II powers this extension of HAT activity. However, two findings in the present study specifically argue against this simple model. The first is that the LCR transcripts 5 0 to HSI are bidirectional, suggesting that they originate at multiple sites rather than uniquely at HSI. The second, and more direct, point is that insertion of an exogenous Pol II termination element within the LCR domain of transcription, between HSI and hGH-N, had no significant impact on histone H3/H4 acetylation within the hGH locus or at the hGH-N promoter. These findings suggest that the roles of HSI in targeting histone acetylation to the hGH locus and in stimulating Pol II tracking through the hGH LCR are not directly linked.
Transcription of LCRs and enhancer elements has been reported in several systems. Intergenic transcripts are generated from the b-globin LCR ( RNA from the pituitaries of hGH/P1 and hGH/P1(TerF) transgenic mice was assayed by semiquantitative RT-PCR using the indicated p5, HSI, and CD79b(exon 6) primer sets followed by gel analysis and Southern hybridization. A parallel RT-PCR assay for b-actin mRNA from each sample was used to control for the quality of the RNA preparations. Presence (+) or absence (2) of RTase is indicated above relevant lanes. The corresponding transgene copy number for each line is indicated below each data set. Transcript signals detected by RT-PCR with each of the three primer sets were normalized to the b-actin mRNA amplification signal and to the transgene copy number of the corresponding line. This value was then divided by the average normalized values from the two hGH/P1 lines. The final value on the y axis reflects the ratio of transcription at each site in each hGH/P1(TerF) line with that in the hGH/P1 transgenic lines. The value for each of the five hGH/P1(TerF) lines at each of the three positions is plotted (shaded squares). acetylation pattern (Haussecker and Proudfoot 2005) . Furthermore, global inhibition of transcriptional elongation fails to redistribute Pol II at the HS core sites or alter histone modifications in the murine b-globin LCR. It is postulated that Pol II in the latter system is directly transferred from LCR sites of recruitment to the target b-globin promoter (Johnson et al., 2003) . Extragenic transcripts have also been identified within the LCR of the MHC class II gene (Masternak et al., 2003) . The similar patterns of histone acetylation and Pol II distribution suggest that in this model system Pol II may distribute HAT activity via a ''piggyback'' mechanism through the MHC class II locus. Recent studies have revealed that androgen receptor (AR) regulation of prostate-specific antigen (PSA) requires both promoter-proximal sequences as well as an upstream enhancer; recruitment of AR and cofactors to both sites creates a loop that facilitates Pol II tracking from the enhancer to the promoter (Wang et al., 2005) . These studies indicate that the mechanisms underlying long-range controls vary among systems. It is noteworthy that in none of these systems has a site-specific blockade of Pol II been used to establish a direct functional link between intergenic transcription and target gene activation.
Pol II Tracking Is Essential to Full hGH LCR Activity
In the present study, we observed that insertion of an exogenous Pol II terminator within the LCR domain of transcription represses expression of the remote hGH-N gene. These results, along with those previously reported (Ho et al., 2002) , suggest significant complexity in HSI action as an LCR component. The establishment of a broad domain of histone acetylation in the LCR and the formation of an LCR domain of transcription are both HSI dependent. However, the results of the current study suggest that acetylation of the locus is not dependent on LCR transcription. The insertion of the TerF element significantly represses Pol II tracking 3 0 to the insertion site but has no apparent effect on histone H3/H4 acetylation in this region. These results suggest that the two HSI-dependent activities, Pol II tracking and histone acetylation, are not mechanistically linked. Thus, these results demonstrate an essential role for LCR transcription in the control of hGH-N gene activity, but they do not address the direct role of histone acetylation in this process.
The fact that TerF insertion results in a unilateral (3 0 ) repression of transcription and has no appreciable impact on the level of LCR transcription 5 0 to the insertion site is important when considering its quantitative impact on hGH-N expression. While TerF insertion results in a mean 6-fold decrease in hGH-N expression (Figure 5) , HSI inactivation represses expression of the linked hGH-N by 20-fold (Ho et al., 2002) . This difference in the extent of hGH-N repression may be directly related to corresponding effects on LCR transcription. While HSI inactivation results in a global loss of transcripts throughout the LCR domain (Figures 1 and 3) , the TerF insertion selectively eliminates transcription 3 0 to the insertion site, namely across the CD79b gene ( Figure 5A ). These data (summarized in Figure 6 ) lead us to propose that Pol II tracking within the hGH LCR domain of transcription acts in an additive fashion; the selective retention of transcription in the LCR 5 0 of the TerF insertion may contribute independently to this process and maintain a moderate residual level of hGH-N expression. Loss of the transcription throughout the entire LCR domain secondary to HSI deletion results in a further incremental loss of hGH-N function. Thus, in the comparison of the hGH/P1, hGH/P1(TerF), and hGH/ P1(DHSI) transgenes, the levels of hGH-N expression appear to be directly related to the overall levels of LCR transcription (Figure 6 ). How does the LCR domain of transcription contribute to long-range gene activation? The gap between the LCR domain of transcription and the hGH-N gene makes it unlikely that the mechanism represents direct linear delivery of polymerase or coactivator complexes from the LCR to the hGH-N promoter. It seems more likely that the act of transcription has a direct effect(s) on LCR structure and that this altered structure triggers subsequent steps in the activation pathway. Pol II tracking can deplete local H2A and H2B histone content (Nacheva et al., 1989) and trigger replacement of standard histones with histone variants (Mito et al., 2005; Wirbelauer et al., 2005) . In addition, it has been shown that complexes containing H3 lysine 4 (H3K4) methyltransferase associate with the elongating (Ser5 phosphorylated) Pol II Ng et al., 2003; SantosRosa et al., 2002) . H3K4 trimethylation is a highly conserved component of an active chromatin environment (Berger, 2002) ; chromodomain proteins are targeted to such H3K4 methylated histones (Flanagan et al., 2005) , and their local action may be critical to LCR function. Thus, by a number of mechanisms, Pol II tracking might create a modified and accessible chromatin conformation that would facilitate subsequent recruitment of coregulators. These effects may enhance direct interactions between one or more LCR determinants and the hGH-N promoter, possibly via looping mechanisms (Tolhuis et al., 2002) . Tracking of Pol II within the LCR domain may also anchor the hGH-N locus to an established nuclear subcompartment in which the hGH-N promoter would have access to enriched sources of Pol II and other transcription factors (Osborne et al., 2004) .
The role of CD79b transcription in hGH LCR action is of particular interest. The initial observation that the B-lymphocyte-specific CD79b gene is robustly transcribed in the pituitary was unexpected (Cajiao et al., 2004) . Although our initial impression was that activation of CD79b in the pituitary reflected a passive response of this gene to the encompassing activated hGH LCR chromatin milieu, its robust nature suggested that it might play an active role in hGH LCR function. The present data (summarized in Figure 6 ) support this active model. Selective elimination of CD79b transcription in pituitary chromatin by the TerF insertion in the hGH LCR is paralleled by a marked repression in hGH-N expression. This observation suggests that the bystander transcription at the CD79b locus in the pituitary, once triggered by HSI action, goes on to enhance LCR function by magnifying the overall level and density of Pol II tracking in the region. This apparent appropriation of the CD79b transcription unit for the purpose of amplifying LCR function may reflect an evolutionary adaptation to its positioning within the hGH locus. The fact that the abundant CD79b mRNA does not encode detectable levels of protein in the pituitary (Cajiao et al., 2004) further suggests that the somatotrope has developed a countervailing mechanism to block the ectopic expression of the potentially toxic CD79b protein product, Igb.
Other mechanistic possibilities that link Pol II tracking with LCR function cannot be eliminated at this time. It remains possible, for example, that LCR transcripts may themselves play a direct role in activation and maintenance of hGH-N expression by recruiting trans-activators to the chromatin sites (Sleutels et al., 2002; Akhtar et al., 2000; Sanchez-Elsner et al., 2006) . By directly targeting these transcripts without concurrently releasing Pol II from the chromatin template, it should be possible to gain further insights into these important distinctions. Such studies will contribute to a more comprehensive understanding of how Pol II tracking and intergenic transcription contribute to long-range control in the mammalian genome.
Experimental Procedures
Detection of Transcripts Emanating from the hGH Locus To generate hyperplastic, somatotrope-enriched pituitaries, each of two hGH/P1 transgenic line (lines 809F and 811D; Su et al., 2000) were crossed with mice carrying a human growth hormone-releasing factor (hGRF) transgene (Mayo et al., 1988) . Pituitary and liver RNAs were prepared from these 3-month-old compound transgenic mice. RNAs from five pituitaries were pooled for each set of assays. RNA was treated with RQ1 DNase (Promega, Madison, Wisconsin) to eliminate DNA contamination. For the analysis of total transcripts at each site along the locus, a cDNA library was first generated. Five micrograms of total RNA was incubated at 42 C for 50 min with reverse transcriptase (RT) along with 300 ng of a random hexamer per 20 ml reaction. RT was heat inactivated, and 2 ml of the treated reactions was used for subsequent sequence-specific PCR. To control for amplification of contaminant DNA, a parallel library was generated in the absence of RT. The RT(+) and RT(2) libraries were assayed in parallel and within the linear range of amplification for the presence of cDNAs corresponding to defined positions across the hGH locus (Figure 1) . The primers used to detect cDNAs at each position can be found in Table S1 . To define the orientation of the noncoding transcripts, 0.5-1 mg of pituitary RNA was reverse transcribed with strand-specific primers prior to PCR amplification with site-specific amplimers (Table S1 ). PCR-generated cDNAs from the library analysis or from the strand-specific analysis were separated on 1.5% agarose gels and Southern hybridized with 32 P-labeled probes generated by the same sets of PCR primers. Each band was quantified by phosphorimager analyses (Molecular Dynamics, Sunnyvale, California). hGH/P1 plasmid DNA was used as the control template to assess the PCR efficiency of each primer set. Serial dilutions of the hGH/P1 plasmid DNA (7-0.007 ng) were assayed to determine the linear range for the PCR amplification (data not shown). In all cases, 0.007 ng fell within the linear range of the signals obtained from the RT-PCR. The RT-PCR signal levels were normalized to the level of PCR signals from 0.007 ng of hGH/P1 plasmid DNA generated with the same set of primers (C; control) and was calculated in arbitrary units.
To quantify transcripts bracketing the TerF element, RT-PCR was performed at sites corresponding to p5, HSI, and exon 6 of CD79b ( Figure 5 ). In each case, the RT-PCR signal was determined to be in the linear range and its value was normalized to the b-actin RT-PCR cDNA product from the same RNA sample to correct for the quantity and quality of the input RNA. The normalized value from each of the five hGH/P1(TerF) pituitary RNA samples was CoRT-PCR Assay for hGH-N Expression Pituitary RNA from transgenic mice carrying hGH/P1 or the hGH/ P1(TerF) transgene was extracted from a single pituitary of each line. The RT-PCR assays were performed as described previously (Jones et al., 1995 , Ho et al., 2002 . The resultant hGH-N to mGH RNA ratios were divided by the relevant transgene copy number to establish transgene expression per copy.
Chromatin Immunoprecipitation Assays
ChIP assays were performed as previously described on compound transgenic (GRF) mice (Ho et al., 2002) . The antibodies recognized the N-terminal sequences of Pol II (Santa Cruz Biotechnology Santa Cruz, California [sc-899]) or the Ser-5-phosphorylated Pol II C-terminal domain (pPol II) (Covance Research Products, Cumberland [VA (H-14, MMS-134R)]). For acetylated H3 and H4 ChIP, the antibodies used recognize diacetylated H3 (06-599) and tetraacetylated H4 (06-598) (Upstate Cell Signaling Solutions, Charlottesville, Virginia). For ChIPs using the pPol II antibody, phosphatase inhibitors (0.5 mM sodium orthovanadate, 10 mM sodium molybdate, and 40 mM bglycerol phosphate) were included in buffers. To precipitate IgMcontaining immune complexes, rabbit anti-mouse IgM (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pennsylvania) was prebound to the protein A-agarose (2 mg/ml) for 3 hr. Normal rabbit serum (Santa Cruz) was used as control for the ChIP assays. The input and bound DNA were amplified by PCR. The sequences and position of the primers used for PCR are summarized in Table  S2 . PCR products were quantified by Southern blotting as described above. A series of dilutions of the chromatin input fraction was used to determine the linear region for the PCR amplification at each site as described (Ho et al., 2002) (Figure 5 and data not shown). The signals of bound fractions were normalized to the signals of 0.03% of the input. The ratio of signal from the bound to input samples was normalized to the ratio of bound to input obtained from the mouse endogenous MyoD gene. The sequences of the primers for MyoD are as previously reported (Sawado et al., 2003) .
Insertion of the Transcriptional Terminator Element into the hGH Locus
The insertion of the human b-globin transcriptional terminator element (TerF) into the hGH/P1 clone was performed by RecA-assisted homologous recombination (Yang et al., 1997; Ho et al., 2002) . TerF, a 2.2 kb DNA fragment from the human b-globin gene (pbD5-7; gift of N. Proudfoot, Oxford University; Dye and Proudfoot, 2001) , was inserted between the hGH LCR and hGH-N (coordinate 213,660 bp relative to the hGH-N transcription start site). This TerF was inserted in the sense orientation relative to hGH-N. Accurate insertion in the resultant hGH/P1(TerF) transgene was confirmed by DNA sequencing. A ''fingerprinting'' approach (Ho et al., 2002) was carried out to confirm that there were no unexpected alterations in the hGH/P1(TerF) DNA (data not shown).
Generation of Transgenic Mouse Lines
The hGH/P1(TerF) DNA was linearized with NotI and purified through an Elutip (Schleicher and Schuell Bioscience, Keene, New Hampshire). The DNA was diluted to 2 ng/ml in 10 mM Tris-HCl (pH 7.5) and 0.1 mM Na 2 EDTA and was microinjected into the pro-nucleus of C57Bl/6J X SJL mouse zygotes. The integrity and copy number of each transgene were determined as described (Su et al., 2000 , Ho et al., 2002 .
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